AstraZeneca's Legal Troubles Continue To Mount
Days after the European Patent Office rejected a key substance-of-matter patent covering drug giant AstraZeneca's blockbuster heartburn drug Nexium, antitrust challenges continue to mount over the drug in the United States....To view the full article, register now.
Already a subscriber? Click here to view full article